Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of drospirenone 3 mg + ethinyl estradiol 0.03 mg vs Yasmin in healthy Thai female volunteers (fasting)
TCTR20211223003Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of drospirenone and ethinyl estradiol in contraception (2 arms), sponsored by Bio-innova. Primary endpoint: Bioequivalence based on pharmacokinetic parameters. Planned start May 2022; status: not yet recruiting.
02
Drugs
drospirenoneethinyl estradiol
03
Conditions
contraception
Beyond the preview
Go deeper on TCTR20211223003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211223003.